Post-doctoral Research Position (3 years) on Cellular plasticity, epigenetic remodeling and resistance to treatment “Génétique et Biologie des Cancers”
Institut Curie, Paris
The laboratory “Genetics and Biology of Pediatric Tumors“ directed by Olivier Delattre at Institut Curie develop several research programs to understand the biology and oncogenic transformation mechanisms of various pediatric tumors. We are particularly interested in the mechanisms that govern cellular plasticity in childhood cancers and their role in treatment resistance. Institut Curie provides an excellent scientific environment for high quality research with state-of-the-art equipments as well as a constellation of seminars covering many resarch areas. The successful post-doctoral applicant will join the neuroblastoma team on a collaborative research project funded by INCa and led by Isabelle Janoueix-Lerosey.
Tumor cell plasticity has now ben identified as a source of intra-tumor heterogeneity that may contribute to treatment failure in several types of cancer. To further explore the mechanisms of plasticity and their link with epigenetic remodeling, we will focus on neuroblastoma, a tumor of the sympathetic nervous system, derived from multipotent neural crest cells (NCC), which accounts for around 15% of children cancer-related deaths. High-Risk neuroblastoma most often initially responds to intensive chemotherapy, however, relapses frequently occur followed by fatal outcome. Through the analysis of the super-enhancer landscape, we recently revealed two types of cell identity in neuroblastoma: a sympathetic noradrenergic identity and a NCC-like identity, driven by a module including the PHOX2B, HAND2 and GATA3 transcription factors (TFs) and a module containing AP-1 TF, respectively (Boeva et al, Nature Genetics, 2017).
We showed that NCC-like cells display mesenchymal features and are less sensitive to chemotherapy. Recent evidence indicates that some neuroblastoma cells exhibit plasticity and are able to shift between a NCC-like/mesenchymal and a noradrenergic identity and vice versa.
The successful candidate will participate in the whole project that aims at investigating neuroblastoma cell identity, plasticity and heterogeneity in neuroblastoma in order to: (1) determine the fundamental mechanisms involved in cell plasticity in vitro; (2) characterize intratumor heterogeneity and plasticity upon treatments using in vivo models; (3) evaluate intratumor heterogeneity in patient samples and investigate the links between heterogeneity and clinical parameters. To answer these questions, we will use cell culture, FACS sorting based on specific markers, RNA-seq at the cell population and single cell levels and ChIP-seq. The understanding of the mechanisms underlying neuroblastoma cell identity and lineage plasticity should provide novel insights into therapy design to improve outcome of high-risk neuroblastoma patients.
It will contribute to a better characterization of the role of cellular reprogramming in tumorigenesis.
We are looking for a highly motivated and innovative post-doc candidate with a PhD degree in life science, preferentially in a relevant discipline (cellular and molecular biology, cancer biology …) with expertise in transcriptomic analysis and epigenetics and experience working with mice.
How to apply
The position (3 years) is available starting between November 2018 and January 2019. Applicants should send their detailed CV, a cover letter and contact information of at least two academic references to firstname.lastname@example.org
Selected publications of the team
Lopez-Delisle L, Pierre-Eugène C, Louis-Brennetot C, Surdez D, Raynal V, Baulande S, Boeva V, Grossetête-Lalami S, Combaret V, Peuchmaur M, Delattre O and Janoueix-Lerosey I. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. Oncogene (2018) 37:1417-1429.
Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, Tirode F. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol. (2018) 245:29-40.
Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, Geoerger B, Orth MF, Grünewald TGP, Diaz E, Ducos B, Surdez D, Carcaboso AM, Medvedeva I, Deller T, Combaret V, Lapouble E, Pierron G, Grossetête-Lalami S, Baulande S, Schleiermacher G, Barillot E, Rohrer H, Delattre O, Janoueix-Lerosey I. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. (2017) 49:1408-1413.
Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E, Chavrier P, Delattre O. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene. (2017) 36:3505-3514
Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Bérard P, Véron AS, Reynaud S, Lapouble E, Boeva V, Rio Frio T, Alonso J, Bhatia S, Pierron G, Cancel-Tassin G, Cussenot O, Cox DG, Morton LM, Machiela MJ, Chanock SJ, Charnay P, Delattre O. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet. (2015) 47:1073-8.
Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, Nicolas A, Provost C, Louis-Brennetot C, Daveau R, Kumps C, Cascone I, Schleiermacher G, Prignon A, Speleman F, Rohrer H, Delattre O, Janoueix-Lerosey I. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget (2014) 5: 2688-2702.
Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, Boeva V, Daveau R, Cappo J, Combaret V, Schleiermacher G, Jouannet S, Ferrand S, Pierron G, Barillot E, Loew D, Vigny M, Delattre O, Janoueix-Lerosey I. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res. (2013) 73:195-204.